Cargando…

Influence of severity of illness on the effects of eritoran tetrasodium (E5564), a TLR4 antagonist, in patients with severe sepsis

Detalles Bibliográficos
Autores principales:	Opal, SM, Kalil, AC, LaRosa, SP, Gogate, J, Lynn, M, Wittek, AE
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2776179/ http://dx.doi.org/10.1186/cc8062

Ejemplares similares

Evaluation of eritoran tetrasodium (E5564), a TLR4 antagonist, on the QTc interval in healthy subjects
por: Nagy, CF, et al.
Publicado: (2011)

Use of a screening authorization and randomization center for severe sepsis patient qualification and real-time enrollment in a phase 2 trial of eritoran tetrasodium (E5564), a TLR4 antagonist
por: Schentag, J, et al.
Publicado: (2009)

Safety, pharmacokinetics, and pharmacodynamics of 4-hour intravenous infusion of eritoran tetrasodium in healthy Japanese and Caucasian males
por: Okubo, Y, et al.
Publicado: (2011)

Respiratory Syncytial Virus Fusion Protein-Induced Toll-Like Receptor 4 (TLR4) Signaling Is Inhibited by the TLR4 Antagonists Rhodobacter sphaeroides Lipopolysaccharide and Eritoran (E5564) and Requires Direct Interaction with MD-2
por: Rallabhandi, Prasad, et al.
Publicado: (2012)

Eritoran: the evidence of its therapeutic potential in sepsis
por: Raja, Shahzad G., et al.
Publicado: (2007)

Eritoran insight for influenza treatment
por: Baas, Tracey
Publicado: (2013)

The Toll-Like Receptor 4 Antagonist Eritoran Protects Mice from Lethal Filovirus Challenge
por: Younan, Patrick, et al.
Publicado: (2017)

0986. The effect of eritoran on the severity of lung injury in two different rat lung injury models
por: Kundakci, A, et al.
Publicado: (2014)

Decreased Protein C, Protein S and Antithrombin III Levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei
por: Larosa, SP, et al.
Publicado: (2000)

Severe Sepsis and Septic Shock
por: Opal, Steven M.
Publicado: (2008)

Effect of the Toll-Like Receptor 4 Antagonist Eritoran on Retinochoroidal Inflammatory Damage in a Rat Model of Endotoxin-Induced Inflammation
por: Ekici, Feyzahan, et al.
Publicado: (2014)

Eritoran Attenuates Hepatic Inflammation and Fibrosis in Mice with Chronic Liver Injury
por: Hsieh, Yun-Cheng, et al.
Publicado: (2021)

Year in review 2008: Critical Care - sepsis
por: Opal, Steven M, et al.
Publicado: (2009)

AB103, a CD28 antagonist peptide: a new therapeutic agent in a model of severe sepsis
por: Teleman, D, et al.
Publicado: (2011)

Tetrasodium EDTA for the prevention of urinary catheter infections and blockages
por: Moore, Jessica V., et al.
Publicado: (2023)

E5564 inhibits immunosuppressive cytokine IL-10 induction promoted by HIV-1 Tat protein
por: Bahraoui, Elmostafa, et al.
Publicado: (2014)

Poly[di-μ(9)-citrato-cobalt(II)tetrasodium]
por: Liu, Zhen, et al.
Publicado: (2012)

The complex link between influenza and severe sepsis
por: Florescu, Diana F, et al.
Publicado: (2014)

Reviewing and identifying amino acids of human, murine, canine and equine TLR4 / MD-2 receptor complexes conferring endotoxic innate immunity activation by LPS/lipid A, or antagonistic effects by Eritoran, in contrast to species-dependent modulation by lipid IVa
por: Scior, Thomas, et al.
Publicado: (2013)

Is cytomegalovirus reactivation increasing the mortality of patients with severe sepsis?
por: Kalil, Andre C, et al.
Publicado: (2011)

Use of tetrasodium EDTA acid for the treatment of intraluminal obstruction of subcutaneous ureteral bypass devices
por: Duval, Valerie, et al.
Publicado: (2022)

Tetrasodium (dihydrogenheptaoxidodigermanato)bis(dihydrogentetraoxidogermanato)dicopper(II) monohydrate
por: Li, Ya-Feng, et al.
Publicado: (2009)

Shape-Controlled Synthesis of Au Nanostructures Using EDTA Tetrasodium Salt and Their Photothermal Therapy Applications
por: Jang, Youngjin, et al.
Publicado: (2018)

Presentation and Clinical Features of Severe Sepsis
por: Green, Justin, et al.
Publicado: (2000)

Comparison of cytotoxicities and wound healing effects of diquafosol tetrasodium and hyaluronic acid on human corneal epithelial cells
por: Lee, Jong Heon, et al.
Publicado: (2017)

Therapeutic use of tetrasodium ethylenediaminetetraacetic acid solution for treatment of subcutaneous ureteral bypass device mineralization in cats
por: Chik, Colin, et al.
Publicado: (2019)

Tracer Studies of Potential Radiosensitizing Agents: Tetrasodium 2-methyl-3-(82)Br-bromo-1: 4-Napthohydroquinone Diphosphate and Tetrasodium 2: 3-dimethyl-5: 6-di(131)-I-iodo-1: 4-benzohydroquinone Diphosphate
por: Marrian, D. H., et al.
Publicado: (1956)

A TLR7 antagonist restricts interferon-dependent and -independent immunopathology in a mouse model of severe influenza
por: Rappe, Julie C.F., et al.
Publicado: (2021)

Hyperuricemia: An Early Marker for Severity of Illness in Sepsis
por: Akbar, Sana R., et al.
Publicado: (2015)

Severe sepsis: are PROWESS and PROWESS-SHOCK trials comparable? A clinical and statistical heterogeneity analysis
por: Kalil, Andre C, et al.
Publicado: (2013)

Tracer Studies of Potential Radiosensitizing Agents. Tetrasodium 2-(14)C-Methyl-1:4-Naphthohydroquinone Diphosphate
por: Marrian, D. H., et al.
Publicado: (1956)

Tetrasodium EDTA Is Effective at Eradicating Biofilms Formed by Clinically Relevant Microorganisms from Patients’ Central Venous Catheters
por: Liu, Fangning, et al.
Publicado: (2018)

Lymphocyte phenotype during severe sepsis and septic shock
por: Le Dorze, M, et al.
Publicado: (2015)

Why Are Clinicians Not Embracing the Results from Pivotal Clinical Trials in Severe Sepsis? A Bayesian Analysis
por: Kalil, Andre C., et al.
Publicado: (2008)

Serum total antioxidant capacity reflects severity of illness in patients with severe sepsis
por: Chuang, Chia-Chang, et al.
Publicado: (2006)

Complement activation in severely ill patients with sepsis: no relationship with inflammation and disease severity
por: de Nooijer, Aline H., et al.
Publicado: (2023)

Acute Oral or Dermal and Repeated Dose 90-Day Oral Toxicity of Tetrasodium Pyrophosphate in Spraque Dawley (SD) Rats
por: Seo, Dong Seok, et al.
Publicado: (2011)

Underweight is associated with mortality in patients with severe sepsis and septic shock
por: Lee, SM, et al.
Publicado: (2015)

Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
por: Dellinger, R. P., et al.
Publicado: (2013)

Induction of severe Staphylococcus aureus sepsis in pigs
por: Iburg, TM, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ih0bitsigil6oiq846sc6ci78k